Martina Hinterleitner

8PUBLICATIONS
29CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Innate immunityPredictive and prognostic markersHaematology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Mar 23, 2026
Senescence-directed nanotherapy ameliorates fibrosis and overcomes immune exclusion in cancer.

Clemens Hinterleitner, Valentin J A Barthet, Hailey V Goldberg

|May 13, 2022
BCR::ABL1 tyrosine kinase inhibitors hamper the therapeutic efficacy of blinatumomab in vitro.

Joseph Kauer, Melanie Märklin, Martin Pflügler

|Feb 04, 2021
Platelet-expressed immune checkpoint regulator GITRL in breast cancer.

Yanjun Zhou, Jonas S Heitmann, Kim L Clar

|Jun 17, 2020
Fc gamma receptor expression serves as prognostic and diagnostic factor in AML.

Jonas S Heitmann, Ilona Hagelstein, Clemens Hinterleitner

|Sep 22, 2019
Disease progression and defects in primary hemostasis as major cause of bleeding in multiple myeloma.

Clemens Hinterleitner, Ann-Christin Pecher, Klaus-Peter Kreißelmeier

|Jul 08, 2018
Long-term remission of refractory Rosai-Dorfman disease after salvage therapy with clofarabine in an adult patient.

Clemens Hinterleitner, Martina Steurer, Daniela Dörfel

Pageof 2